x
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the fiscal year ended December 31, 2008
|
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
|
For
the transition period from _______________________to
_________________________
|
Delaware
|
22-3367588
|
|
(State
or jurisdiction of
|
(I.R.S.
Employer
|
|
incorporation
or organization)
|
Identification
No.)
|
Indicate
by check mark if the registrant is a well-known seasoned issuer, as
defined in Rule 405 of the Securities Act.
|
|
o Yes
x
No
|
|
Indicate
by check mark if the registrant is not required to file reports pursuant
to Section 13 or 15 (d) of the Act.
|
|
o Yes
x
No
|
|
Indicate
by check mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
|
|
x
Yes o
No
|
|
Indicate
by check mark if disclosure of delinquent filers in response to Item 405
of Regulation S-K (§229.405 of this chapter) is not contained herein, and
will not be contained, to the best of registrant’s knowledge, in
definitive proxy or information statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K.
|
|
|
o
|
Large accelerated
filer o
|
Accelerated filer
o
|
Non-accelerated
filer o (Do not
check if a smaller reporting company)
|
Smaller reporting
company x
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 under the Exchange Act).
|
|
o Yes
x
No
|
Note
Concerning Forward Looking Information
|
3
|
|||
PART
I
|
||||
ITEM
1.
|
BUSINESS
|
4
|
||
ITEM
1A.
|
RISK
FACTORS
|
10
|
||
ITEM
1B.
|
UNRESOLVED
STAFF COMMENTS
|
10
|
||
ITEM
2.
|
PROPERTIES
|
11
|
||
ITEM
3.
|
LEGAL
PROCEEDINGS
|
11
|
||
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
11
|
||
PART
II
|
||||
ITEM
5.
|
MARKET
FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF
EQUITY SECURITIES.
|
11
|
||
ITEM
6.
|
SELECTED
FINANCIAL DATA
|
12
|
||
ITEM
7.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
12
|
||
ITEM
7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
|
16
|
||
ITEM
8.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
|
16
|
||
ITEM
9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
|
16
|
||
ITEM
9A(T)
|
CONTROLS
AND PROCEDURES
|
16
|
||
ITEM
9B.
|
OTHER
INFORMATION
|
17
|
||
PART
III
|
||||
ITEM
10.
|
DIRECTORS,
EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
|
17
|
||
ITEM
11.
|
EXECUTIVE
COMPENSATION
|
20
|
||
ITEM
12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
|
25
|
||
ITEM
13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE
|
27
|
||
ITEM
14.
|
PRINCIPAL
ACOUNTING FEES AND SERVICES
|
28
|
||
PART
IV
|
||||
ITEM
15.
|
EXHIBITS,
FINANCIAL STATEMENT SCHEDULES
|
29
|
●
|
The
development of new products and the expansion of the market for our
current products;
|
|
●
|
Implementing
aspects of our business plans;
|
|
●
|
Financing
goals and plans;
|
|
●
|
Our
existing cash and whether and how long these funds will be sufficient to
fund our operations; and
|
|
●
|
Our
raising of additional capital through future equity
financings.
|
ITEM
1.
|
BUSINESS.
|
1(a)
|
Business
Development
|
1(b)
|
Business
of the Issuer
|
ITEM
1A.
|
RISK
FACTORS
|
ITEM
1B.
|
UNRESOLVED
STAFF COMMENTS
|
ITEM
2.
|
PROPERTIES
|
ITEM
3.
|
LEGAL
PROCEEDINGS
|
ITEM
4.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS
|
ITEM
5.
|
MARKET
FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND SMALL BUSINESS ISSUER
PURCHASES OF EQUITY
SECURITIES.
|
5(a)
|
Market
Information.
|
Year
ended December 31, 2008
|
|
High
|
Low
|
||||||
First
Quarter
|
$ | 0.68 | $ | 0.40 | |||||
Second
Quarter
|
$ | 0.53 | $ | 0.28 | |||||
Third
Quarter
|
$ | 0.30 | $ | 0.22 | |||||
Fourth
Quarter
|
$ | 0.30 | $ | 0.12 | |||||
Year
ended December 31, 2007
|
|
High
|
Low
|
||||||
First
Quarter
|
$ | 2.35 | $ | 1.08 | |||||
Second
Quarter
|
$ | 2.65 | $ | 1.65 | |||||
Third
Quarter
|
$ | 3.38 | $ | 1.55 | |||||
Fourth
Quarter
|
$ | 1.80 | $ | 0.55 |
5(b)
|
Holders
|
5(c)
|
Dividends
|
5(d)
|
Recent
Sales of Unregistered Securities
|
5(d)(i)
|
Recent
Sales of Unregistered
Securities
|
ITEM
6.
|
SELECTED
FINANCIAL DATA
|
ITEM
7.
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
|
7(a)
|
Introduction
|
7(b)
|
Results
of Operations - Years Ended December 31, 2008 and
2007
|
7(c)
|
Liquidity
and Capital Resources
|
7(d)
|
Impact
of Inflation
|
7(e)
|
Seasonality
|
7(f)
|
Impact
of Recently Issued Financial Accounting
Standards
|
7(g)
|
Off-Balance
Sheet Arrangements
|
7(h)
|
Critical
Accounting Policies
|
ITEM
7A.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
|
ITEM
8.
|
FINANCIAL
STATEMENTS
|
ITEM
9.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
|
ITEM
9A(T)
|
CONTROLS
AND PROCEDURES
|
(a)
|
Evaluation
of Disclosure Controls and
Procedures
|
(b)
|
Changes
in Internal Controls Over Financial
Reporting
|
(i)
|
pertain
to the maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the
company;
|
|
(ii)
|
provide
reasonable assurance that transactions are recorded as necessary to permit
preparation of financial statements in accordance with U.S. generally
accepted accounting principles, and that receipts and expenditures of the
company are being made only in accordance with authorizations of
management and directors of the company; and
|
|
(iii)
|
provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use or disposition of the company’s assets that
could have a material effect on the financial
statements.
|
ITEM
9B
|
OTHER
INFORMATION
|
ITEM
10.
|
DIRECTORS,
EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE
|
|
10(a)
|
Directors
and Executive Officers
|
Name
|
Position
|
||||
Robert
Portman, Ph.D.
|
Chairman
of the Board of Directors
|
||||
Jason
Ash
|
President,
Chief Executive Officer, and Director
|
||||
Stephen
P. Kuchen
|
Chief
Financial Officer, Treasurer, and Secretary
|
||||
David
Portman
|
Director
|
||||
Michael
Cahr
|
Director 1,2,3
|
||||
Adam
Mizel
|
Director 1,2
|
||||
Marc
Particelli
|
Director 2,3
|
1
Member of Audit Committee
|
|
2
Member of Compensation Committee
|
|
3
Member of Nominating/Governance
Committee
|
10(b)
|
Scientific
Advisory Boards
|
We
do not have a formal established Scientific Advisory Board but as the need
arises, we consult with individual scientists on a non-scheduled
basis.
|
|
10(c)
|
Family
Relationships
|
Robert
Portman and David Portman are brothers. There are no other family
relationships among our directors, executive officers or persons nominated
or chosen to become directors or executive officers of
ours.
|
|
10(d)
|
Involvement
in Certain Legal Proceedings
|
No
events have occurred during the past five years that are required to be
disclosed pursuant to Item 401(d) of Regulation S-B.
|
|
CORPORATE
GOVERNANCE
|
|
10(e)
|
Procedures
for Nomination of Directors by Security Holders
|
There
were no material changes to the procedures for nomination of directors by
the Company’s security holders during the year ended December 31,
2008.
|
|
10(f)
|
Audit
Committee
|
10(g)
|
Audit
Committee Financial
Expert
|
10(h)
|
Section
16(a) Beneficial Ownership Reporting
Compliance
|
o
|
The
Statement of Changes in Beneficial Ownership of Securities on Form 4 filed
by Robert Portman was filed late. This Form 4 disclosed the acquisition by
Dr. Portman of shares of our common stock at market prices on June 25,
2008, June 27, 2008, July 7, 2008 and July 11, 2008.
|
10(i)
|
Code
of Ethics
|
ITEM
11.
|
EXECUTIVE
COMPENSATION
|
Name
and Principal
Position
|
Year
|
Salary
($)
|
Bonus
($)
|
Stock
Awards
($)
|
Option
Awards
($)
|
Non-
Equity
Incentive
Plan
Compen-
sation
($)
|
Nonqualified
Deferred
Compensa-
tion
Earnings
($)
|
All
Other
Compensa-
tion
($)
|
Total
($)
|
|||||||||||||||||||
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
(j)
|
|||||||||||||||||||
Jason
Ash,
|
2008
|
$
|
295,000
|
(1)
|
—
|
__
|
$
|
79,352
|
(2)
|
__
|
__
|
$
|
55,000
|
(1)
|
$
|
429,352
|
||||||||||||
President,
Chief
|
||||||||||||||||||||||||||||
Executive
Officer and
|
||||||||||||||||||||||||||||
a
Director
|
||||||||||||||||||||||||||||
Robert
Portman,
|
2008
|
$
|
172,083
|
(3)
|
——
|
—
|
$
|
216,883
|
(2)(3)
|
—
|
—
|
$
|
129,740
|
(4)
|
$
|
518,706
|
||||||||||||
Chairman
of the
|
|
|
||||||||||||||||||||||||||
Board,
Chief
|
2007
|
$
|
295,000
|
—
|
—
|
$
|
134,484
|
(2)
|
—
|
—
|
$
|
11,700
|
(5)
|
$
|
441,184
|
|||||||||||||
Executive
Officer,
|
|
|
|
|||||||||||||||||||||||||
President
and Chief
|
||||||||||||||||||||||||||||
Scientific
Officer
|
||||||||||||||||||||||||||||
Stephen
P. Kuchen,
|
2008
|
$
|
154,500
|
—
|
—
|
$
|
32,439
|
(2)
|
—
|
—
|
$
|
0
|
(6)
|
$
|
186,939
|
|||||||||||||
Chief
Financial
|
2007
|
$
|
150,000
|
$
|
4,000
|
—
|
$
|
43,528
|
(2)
|
—
|
—
|
$
|
0
|
(6)
|
$
|
197,528
|
||||||||||||
Officer,
Treasurer,
|
||||||||||||||||||||||||||||
and
Secretary
|
Executive
Officer
|
Number
of Shares of Common
Stock
Underlying Options
|
Exercise
Price
|
Grant
Date
|
|||||||
Stephen
Kuchen
|
50,000
|
$
|
0.23
|
September
17, 2008
|
Option
Awards
|
Stock
Awards
|
|||||||||||||||||||||||||||
Name
|
Number
of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
Number
of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
Equity
Incentive
Plan
Awards:
Number
of
Securities
Underlying
Unexercised
Unearned
Options
(#)
|
Option
Exercise
Price
($)
|
Option
Expiration
Date
|
Number
of
Shares
or
Units
of
Stock
That
Have
Not
Vested
(#)
|
Market
Value
of
Shares
or
Units
of
Stock
That
Have
Not
Vested
($)
|
Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units
or
Other Rights
That
Have Not
Vested
(#)
|
Equity
Incentive
Plan
Awards:
Market
or
Payout
Value
of
Unearned
Shares,
Units
or
Other Rights
That
Have Not
Vested
($)
|
|||||||||||||||||||
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
(i)
|
(j)
|
|||||||||||||||||||
Jason
Ash,
|
—
|
600,000
|
(1)
|
—
|
$
|
0.65
|
01/13/2013
|
—
|
—
|
—
|
—
|
|||||||||||||||||
President,
Chief
|
||||||||||||||||||||||||||||
Executive
Officer and
|
||||||||||||||||||||||||||||
a
Director
|
||||||||||||||||||||||||||||
Stephen
P. Kuchen,
|
—
|
50,000
|
(2)
|
—
|
$
|
0.23
|
09/17/2013
|
—
|
—
|
—
|
—
|
|||||||||||||||||
Chief
Financial
|
||||||||||||||||||||||||||||
Officer,
Treasurer,
|
33,333
|
(3)
|
16,667
|
(3)
|
—
|
$
|
1.13
|
12/13/2011
|
||||||||||||||||||||
and
Secretary
|
||||||||||||||||||||||||||||
66,666
|
(4)
|
33,334
|
(4)
|
—
|
$
|
0.60
|
02/13/2011
|
|||||||||||||||||||||
120,000
|
(5)
|
—
|
—
|
$
|
0.70
|
10/01/2009
|
Name
|
Fees
Earned
or
Paid
in
Cash
($)
|
Stock
Awards
($)
|
Option
Awards
($)
|
Non-Equity
Incentive
Plan
Compensation
($)
|
Nonqualified
Deferred
Compensation
Earnings
($)
|
All
Other
Compensation
($)
|
Total
($)
|
|||||||||||||||
(a)
|
(b)
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
(h)
|
|||||||||||||||
David
I. Portman
|
—
|
$
|
19,100
|
$
|
28,425
|
(1)
|
—
|
—
|
—
|
$
|
47,525
|
|||||||||||
Michael
Cahr
|
—
|
$
|
19,100
|
$
|
28,425
|
(1)
|
—
|
—
|
—
|
$
|
47,525
|
|||||||||||
Adam
Mizel
|
—
|
$
|
19,100
|
$
|
18,980
|
(1)
|
—
|
—
|
—
|
$
|
38,080
|
|||||||||||
Marc
Particelli
|
—
|
$
|
19,100
|
$
|
18,980
|
(1)
|
—
|
—
|
—
|
$
|
38,080
|
|||||||||||
Robert
Portman
|
—
|
$
|
12,500
|
—
|
—
|
—
|
—
|
$
|
12,500
|
|||||||||||||
ITEM
12.
|
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED
STOCKHOLDER MATTERS
|
Name
and Address (1)
|
Common
Stock (2)
Amount
Beneficially Owned
|
Common
Stock (2)
Percentage
of Class
|
||||||
Jason
Ash (3)
|
||||||||
President,
Chief Executive Officer and a Director
|
458,000
|
3.1
|
%
|
|||||
Stephen
P. Kuchen (4)
|
||||||||
Vice
President, Chief Financial Officer, Secretary and
Treasurer
|
274,030
|
1.9
|
%
|
|||||
Robert
Portman (5)
|
||||||||
Chairman
of the Board and a Director
|
3,325,425
|
21.5
|
%
|
|||||
David
I. Portman (6)
|
||||||||
Secretary
and a Director
|
604,012
|
4.1
|
%
|
|||||
Michael
Cahr (7)
|
||||||||
Director
|
384,560
|
2.6
|
%
|
|||||
Adam
Mizel (8)
|
||||||||
Director
|
584,840
|
4.0
|
%
|
|||||
Marc
Particelli (9)
|
||||||||
Director
|
216,114
|
1.5
|
%
|
|||||
Executive
Officers and Directors as a group (7 persons)
|
5,846,981
|
36.2
|
%
|
(1)
|
Except
as otherwise indicated, the address of each person named in the above
table is c/o PacificHealth Laboratories, Inc., 100 Matawan Road, Suite
420, Matawan, NJ 07747.
|
(2)
|
Common
Stock which is issuable upon the exercise of a stock option which is
presently exercisable or which becomes exercisable within sixty days is
considered outstanding for the purpose of computing the percentage
ownership (x) of persons holding such options, and (y) of officers and
directors as a group with respect to all options held by officers and
directors.
|
(3)
|
Includes
150,000 shares issuable upon the exercise of options not under any
Incentive Stock plan (“NON-ISO”).
|
(4)
|
Includes
133,334 shares issuable upon the exercise of options granted under our
1995 Plan and 120,000 shares issuable upon the exercise of options granted
not covered under any Plan (“NON-ISO”).
|
(5)
|
Includes
1,025,000 shares issuable upon the exercise of options not under any
Incentive Stock plan (“NON-ISO”). Does not include 200,000 shares of
Common Stock owned by Jennifer Portman, Dr. Portman’s wife, individually
and as Trustee for his and her minor children, as to which Dr. Portman
disclaims beneficial ownership.
|
(6)
|
Includes
70,000 shares issuable upon the exercise of options granted under our 1995
Plan and 35,000 shares issuable upon the exercise of options granted under
our 2000 Plan.
|
(7)
|
Includes
40,000 shares issuable upon the exercise of options granted under our 1995
Plan and 20,000 shares issuable upon the exercise of options granted under
our 2000 Plan.
|
(8)
|
Includes
447,780 shares that are owned by Aquifer Opportunity Fund, L.P., of which
Mr. Mizel is the managing principal of the general partner and 40,000
shares issuable upon the exercise of options granted under our 2000 Plan.
Mr. Mizel disclaims beneficial ownership of the shares owned by Aquifer
Opportunity Fund, L.P. except to the extent of his pecuniary interest
therein.
|
(9)
|
Includes
40,000 shares issuable upon the exercise of options granted under our 2000
Plan.
|
Plan
Category
|
Number
of securities to be
issued
upon exercise of
outstanding
options,
warrants
and rights
|
Weighted-average
exercise
price
of outstanding
options,
warrants and rights
|
Number
of securities
remaining
available for
future
issuance under
equity
compensation plans
(excluding
securities
reflected
in column (a))
|
||||||||
(a)
|
(b)
|
(c)
|
|||||||||
Equity
compensation plans approved by security holders
|
547,250
|
$
|
0.85
|
410,250
|
|||||||
Equity
compensation plans not approved by security holders
|
2,395,000
|
$
|
0.62
|
N/A
|
|||||||
Total
|
2,942,250
|
$
|
0.66
|
410,250
|
ITEM
13.
|
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR
INDEPENDENCE
|
ITEM
14.
|
PRINCIPAL
ACCOUNTING FEES AND SERVICES
|
Fee
Category
|
Fiscal
2008
|
Fiscal
2007
|
||||||
Audit
Fees¹
|
$
|
95,875
|
$
|
90,463
|
||||
Audit-Related
Fees2
|
$
|
- 0
-
|
$
|
- 0
-
|
||||
Tax Fees3
|
$
|
3,300
|
$
|
10,105
|
||||
All Other Fees4
|
$
|
- 0
-
|
$
|
5,000
|
||||
TOTAL
|
$
|
99,175
|
$
|
105,568
|
ITEM
15.
|
EXHIBITS
|
By:
|
/s/Jason
Ash
|
|
Jason
Ash, President and Chief Executive Officer
|
||
Date:
March 16, 2009
|
/s/Jason
Ash
|
Director,
President and Chief
|
March
16, 2009
|
||
Jason
Ash
|
Executive
Officer (Principal Executive Officer)
|
|||
/s/Stephen
P. Kuchen
|
Chief
Financial Officer (Principal
|
March
16, 2009
|
||
Stephen
P. Kuchen
|
Financial
and Accounting Officer) and Secretary
|
|||
/s/Robert
Portman
|
Chairman
of the Board and Director
|
March
16, 2009
|
||
Robert
Portman
|
||||
/s/David
I. Portman
|
Director
|
March
16, 2009
|
||
David
I. Portman
|
||||
/s/Michael
Cahr
|
Director
|
March
16, 2009
|
||
Michael
Cahr
|
||||
/s/
Adam Mizel
|
Director
|
March
16, 2009
|
||
Adam
Mizel
|
||||
/s/
Marc Particelli
|
Director
|
March
16, 2009
|
||
Marc
Particelli
|
Exhibit
No.
|
Description
|
Incorporated
by
Reference
|
|
||||||
3.1
|
—
|
Certificate
of Incorporation of PacificHealth Laboratories, Inc. and all amendments
thereto
|
A
|
||||||
3.2
|
—
|
Amended
and Restated Bylaws of PacificHealth Laboratories, Inc.
|
C
|
||||||
3.3
|
—
|
Certificate
of Amendment of Certificate of Incorporation of PacificHealth
Laboratories, Inc.
|
H
|
||||||
3.4
|
Certificate
of Designations For Series A Preferred Stock
|
I
|
|||||||
4.1
|
—
|
Specimen
Common Stock Certificate
|
C
|
||||||
4.2
|
—
|
Stock
Purchase Agreement dated June 1, 2001 between Pacific Health Laboratories,
Inc. and Glaxo Wellcome International B.V.
|
E
|
||||||
10.1†
|
—
|
Incentive
Stock Option Plan of 1995
|
A
|
||||||
10.2
|
—
|
Strategic
Alliance Agreement between the Company and the Institute of Nutrition and
Food Hygiene
|
A
|
||||||
10.3
|
—
|
Exclusive
Licensing Agreement between the Company and the INFH
|
A
|
||||||
10.4
|
—
|
Shareholders
Agreement
|
A
|
||||||
10.5†
|
—
|
2000
Incentive Stock Option Plan
|
D
|
||||||
10.6†
|
Employment
Extension Agreement between PacificHealth Laboratories, Inc. and Robert
Portman effective September 1, 2004, executed February 28,
2006
|
J
|
|||||||
10.8
|
Asset
Purchase Agreement dated February 22, 2006 between PacificHealth
Laboratories, Inc. and Mott’s LLP (redacted, subject to request for
confidential treatment)
|
L
|
|||||||
10.9
|
License
Agreement dated February 22, 2006 between PacificHealth Laboratories, Inc.
and Mott’s LLP (redacted, subject to request for confidential
treatment)
|
L
|
|||||||
10.10
|
Consulting,
License and Noncompetition Agreement dated February 22, 2006 among
PacificHealth Laboratories, Inc., Mott’s LLP, and Robert Portman
(redacted, subject to request for confidential treatment)
|
L
|
|||||||
10.11†
|
Option
Certificate for grant to Robert Portman
|
M
|
|||||||
10.12†
|
Option
Certificate for grant to Stephen Kuchen under the PacificHealth
Laboratories, Inc. 1995 Incentive Stock Option
Plan.
|
M
|
10.13
|
Form
of Stock Purchase Agreement entered into among the Company, Aquifer
Opportunity Fund, L.P. and Marc C. Particelli.
|
N
|
||||
10.14
|
Form
of Grant Instrument under PacificHealth Laboratories, Inc. 2000 Incentive
Stock Option Plan for Adam M. Mizel.
|
N
|
||||
10.15
|
Form
of Grant Instrument under PacificHealth Laboratories, Inc. 2000 Incentive
Stock Option Plan for Marc C. Particelli
|
N
|
||||
10.16
|
Employment
Agreement, effective January 3, 2008, by and between PacificHealth
Laboratories, Inc. and Jason Ash
|
O
|
||||
10.17
|
Separation
and Release Agreement, effective August 1, 2008, by and between
PacificHealth Laboratories, Inc. and Robert Portman
|
P
|
||||
10.18
|
Amendment
No. 1 to Employment Agreement, by And between PacificHealth Laboratories,
Inc. and Jason Ash, effective August 1, 2008
|
P
|
||||
10.19†
|
Summary
of Compensation for Executive Officers of PacificHealth Laboratories,
Inc.
|
*
|
||||
23.1
|
—
|
Consent
of Weiser LLP
|
*
|
|||
31.1
|
—
|
Rule
13a-14(a) Certification of Chief Executive Officer.
|
*
|
|||
31.2
|
—
|
Rule
13a-14(a) Certification of Chief Financial Officer.
|
*
|
|||
32
|
—
|
Certifications
of Chief Executive Officer and Chief Financial Officer pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.
|
*
|
*
|
Filed
herewith
|
†
|
Management
contract or management compensatory plan or
arrangement.
|
A
|
Filed
with Registration Statement on Form SB-2 (Registration No. 333-36379) (the
“1997 SB-2”) on September 25, 1997.
|
B
|
Filed
with Amendment No. 1 to the 1997 SB-2 on October 23,
1997.
|
C
|
Filed
with Amendment No. 3 to the 1997 SB-2 on December 17,
1997.
|
D
|
Filed
with Definitive Proxy Statement (Schedule 14A) for annual meeting held on
August 16, 2000, filed on July 11, 2000.
|
E
|
Filed
with Current Report on Form 8-K dated June 1, 2001, filed on
June 14, 2001.
|
F
|
Filed
with Annual Report on Form 10-KSB for the year ended December 31,
2001.
|
G
|
Filed
with Amendment to Current Report on Form 8-K dated June 1, 2001,
filed July 5, 2001.
|
H
|
Filed
with Annual Report on Form 10-KSB for the year ended December 31,
2002.
|
I
|
Filed
as Exhibit 3.1 to Current Report on Form 8-K, dated January 24, 2005,
filed on January 28, 2005.
|
J
|
Filed
as Exhibit 10.1 to Current Report on Form 8-K, dated and filed on
September 9, 2004.
|
K
|
Filed
with Annual Report on Form 10-KSB for the year ended December 31,
2004.
|
L
|
Filed
with Annual Report on Form 10-KSB for the year ended December 31,
2005.
|
M
|
Filed
as Exhibit to Current Report on Form 8-K, dated December 13, 2006 and
filed on December 19, 2006.
|
N
|
Filed
as Exhibit to Current Report on Form 8-K, dated February 22, 2007 and
filed February 27, 2007.
|
O
|
Filed
as Exhibit to Current Report on Form 8-K, dated November 28, 2007 and
filed December 3, 2007.
|
P
|
Filed
as Exhibit to the Annual report on Form 10-KSB filed on March 31,
2006.
|
Contents
|
|||
Page
|
|||
Financial
Statements
|
|||
Report
of independent registered public accounting firm
|
F-1
|
||
Balance
sheets as of December 31, 2008 and 2007
|
F-2
|
||
Statements
of operations for the years ended December 31, 2008 and
2007
|
F-3
|
||
Statements
of changes in stockholders’ equity for the years ended December 31, 2008
and 2007
|
F-4
|
||
Statements
of cash flows for the years ended December 31, 2008 and
2007
|
F-5
|
||
Notes
to financial statements
|
F-6
|
December
31,
|
||||||||
2008
|
2007
|
|||||||
ASSETS
|
||||||||
Current
assets:
|
||||||||
Cash
and cash equivalents
|
$ | 888,993 | $ | 1,712,713 | ||||
Other
short-term investments
|
300,000 | — | ||||||
Accounts
receivable, net of allowances of $24,000 and $20,000,
respectively
|
455,851 | 709,623 | ||||||
Inventories
(including consigned inventory of approximately $156,000 and $261,000,
respectively)
|
1,308,316 | 2,010,446 | ||||||
Prepaid
expenses
|
159,200 | 111,672 | ||||||
Total
current assets
|
3,112,360 | 4,544,454 | ||||||
Property
and equipment, net
|
236,721 | 185,007 | ||||||
Deposits
|
22,895 | 10,895 | ||||||
TOTAL
ASSETS
|
$ | 3,371,976 | $ | 4,740,356 | ||||
LIABILITIES
|
||||||||
Current
liabilities:
|
||||||||
Notes
payable
|
$ | 58,810 | $ | 16,205 | ||||
Accounts
payable and accrued expenses
|
555,354 | 472,475 | ||||||
Deferred
revenue
|
347,945 | 559,876 | ||||||
962,109 | 1,048,556 | |||||||
Commitments
|
||||||||
STOCKHOLDERS’
EQUITY
|
||||||||
Preferred
stock, $0.01 par value; 1,000,000 shares authorized, -0- shares issued and
outstanding at December 31, 2008 and December 31, 2007
|
— | — | ||||||
Common
stock, $0.0025 par value, authorized 50,000,000 shares; issued and
outstanding 14,194,613 shares at December 31, 2008 and 13,501,426 shares
at December 31, 2007
|
35,486 | 33,754 | ||||||
Additional
paid-in capital
|
19,585,297 | 18,874,609 | ||||||
Accumulated
deficit
|
(17,210,916 | ) | (15,216,563 | ) | ||||
2,409,867 | 3,691,800 | |||||||
TOTAL
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
$ | 3,371,976 | $ | 4,740,356 |
Years
Ended
December
31,
|
||||||||
2008
|
2007
|
|||||||
Revenue:
|
||||||||
Net
product sales
|
$ | 7,235,991 | $ | 7,427,857 | ||||
Cost
of goods sold:
|
||||||||
Product
sales
|
4,009,817 | 4,445,978 | ||||||
Write-down
of inventories
|
201,697 | 439,208 | ||||||
4,211,514 | 4,885,186 | |||||||
Gross
profit
|
3,024,477 | 2,542,671 | ||||||
Operating
expenses:
|
||||||||
Sales
and marketing
|
898,914 | 917,510 | ||||||
General
and administrative
|
3,542,483 | 2,774,824 | ||||||
Research
and development
|
150,767 | 211,078 | ||||||
Restructuring
expense
|
472,069 | — | ||||||
5,064,233 | 3,903,412 | |||||||
Loss
before other income (expense) and provision for income
taxes
|
(2,039,756 | ) | (1,360,741 | ) | ||||
Other
income (expense):
|
||||||||
Interest
income
|
45,575 | 71,734 | ||||||
Interest
expense
|
(1,468 | ) | (3,496 | ) | ||||
Other
income
|
1,296 | 16,444 | ||||||
45,403 | 84,682 | |||||||
Loss
before income taxes
|
(1,994,353 | ) | (1,276,059 | ) | ||||
Provision
for income taxes
|
— | — | ||||||
Net
loss applicable to common stockholders
|
$ | (1,994,353 | ) | $ | (1,276,059 | ) | ||
Net
loss per common share - basic
|
($ | 0.15 | ) | ($ | 0.10 | ) | ||
Net
loss per common share - diluted
|
($ | 0.15 | ) | ($ | 0.10 | ) | ||
Weighted
average shares outstanding - basic
|
13,660,019 | 13,313,995 | ||||||
Weighted
average shares outstanding – diluted
|
13,660,019 | 13,313,995 |
Additional
Paid
In
|
||||||||||||||||||||||||||||
Preferred
Stock
|
Common
Stock
|
Accumulated
Deficit
|
||||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Total
|
|||||||||||||||||||||||
Balance,
January 1, 2007
|
— | $ | — | 12,776,690 | $ | 31,942 | $ | 17,867,945 | $ | (13,940,504 | ) | $ | 3,959,383 | |||||||||||||||
Fair
value of stock options issued
|
274,890 | 274,890 | ||||||||||||||||||||||||||
Common
stock issued
|
243,243 | 608 | 449,392 | 450,000 | ||||||||||||||||||||||||
Stock
options/warrants exercised
|
481,493 | 1,204 | 282,382 | 283,586 | ||||||||||||||||||||||||
Net
loss
|
(1,276,059 | ) | (1,276,059 | ) | ||||||||||||||||||||||||
Balance,
December 31, 2007
|
— | — | 13,501,426 | 33,754 | 18,874,609 | (15,216,563 | ) | 3,691,800 | ||||||||||||||||||||
Fair
value of stock options issued
|
473,520 | 473,520 | ||||||||||||||||||||||||||
Common
stock issued
|
500,000 | 1,250 | 148,750 | 150,000 | ||||||||||||||||||||||||
Common
stock granted to directors
|
193,187 | 482 | 50,918 | 51,400 | ||||||||||||||||||||||||
Common
stock issuable to directors
|
37,500 | 37,500 | ||||||||||||||||||||||||||
Net
loss
|
(1,994,353 | ) | (1,994,353 | ) | ||||||||||||||||||||||||
Balance,
December 31, 2008
|
— | $ | — | 14,194,613 | $ | 35,486 | $ | 19,585,297 | $ | (17,210,916 | ) | $ | 2,409,867 |
Years
Ended December 31,
|
||||||||
2008
|
2007
|
|||||||
Cash
flows from operating activities:
|
||||||||
Net
loss
|
$ | (1,994,353 | ) | $ | (1,276,059 | ) | ||
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
||||||||
Depreciation
|
159,997 | 96,374 | ||||||
Allowance
for doubtful accounts
|
12,000 | (10,516 | ) | |||||
Equity
instrument-based expense
|
423,986 | 274,890 | ||||||
Write-off
of packaging inventories
|
— | 49,135 | ||||||
Reserve/write-off
of inventories
|
201,697 | 439,208 | ||||||
Restructuring
expense
|
344,143 | — | ||||||
Changes
in:
|
||||||||
Accounts
receivable
|
241,772 | (196,873 | ) | |||||
Prepaid
expenses
|
(47,528 | ) | 32,387 | |||||
Inventories
|
316,060 | (585,514 | ) | |||||
Deposits
|
(12,000 | ) | — | |||||
Accounts
payable and accrued expenses
|
61,543 | (488,282 | ) | |||||
Deferred
revenue
|
(211,931 | ) | 315,679 | |||||
Net
cash used in operating activities
|
(504,614 | ) | (1,349,571 | ) | ||||
Cash
flows from investing activities:
|
||||||||
Proceeds
from sales of other short-term investments
|
1,200,000 | — | ||||||
Purchase
of property and equipment
|
(211,711 | ) | (207,218 | ) | ||||
Net
cash provided by (used in) investing activities
|
988,289 | (207,218 | ) | |||||
Cash
flows from financing activities:
|
||||||||
Proceeds
from common stock issuance
|
150,000 | 450,000 | ||||||
Proceeds
from common stock options/warrants exercised
|
— | 283,586 | ||||||
Proceeds
of note payable
|
101,116 | 79,305 | ||||||
Repayment
of note payable
|
(58,511 | ) | (107,427 | ) | ||||
Net
cash provided by financing activities
|
192,605 | 705,464 | ||||||
Net
increase (decrease) in cash and cash equivalents
|
676,280 | (851,325 | ) | |||||
Cash
and cash equivalents at beginning of year
|
1,712,713 | 2,564,038 | ||||||
Reclassification
of other short-term investments
|
(1,500,000 | ) | — | |||||
Cash
and cash equivalents at end of year
|
$ | 888,993 | $ | 1,712,713 | ||||
Supplemental
disclosures of cash flow information:
|
||||||||
Cash
paid for interest
|
$ | 1,468 | $ | 3,496 | ||||
Cash
paid for income taxes
|
$ | 1,879 | $ | 20,408 |
Note A - The Company
and Significant Accounting Policies
|
|
[1]
|
The
Company:
|
The
Company was incorporated in April 1995 to discover, develop, and
commercialize nutritional products. The Company focuses on the
development, marketing, and selling of patented premium nutrition tools
that enable consumers to enhance their health and improve their
performance. The Company’s principle areas of focus are sports performance
and recovery, including optimal weight management. The Company utilizes
third-party contractors to manufacture all products.
|
|
On
February 22, 2006, the Company sold the trademarks, technology, and
patents for its sports nutrition brands, Accelerade®
and Endurox®
R4
® to Mott’s LLP (“Mott’s”). Simultaneously, the Company and Mott’s
entered into a License Agreement giving the Company the exclusive,
royalty-free right to continue to sell these products in powder, gel and
pill form. Consequently, the Company will continue to market its current
sports nutrition products in the same manner as prior to the sale of the
intellectual property assets. Mott’s launched ACCELERADE Ready To Drink
(“RTD”) in the second quarter of 2007 but discontinued the product in
2008. Therefore, the Company does not expect to receive any royalties from
Mott’s in the near future.
|
|
During
the quarter ended September 30, 2008, the Company made the decision to
restructure to be better able to sustain its base sports performance
business. The Company eliminated a number of positions and chose to exit
certain market sectors. As a result of these decisions, the Company
recorded a restructuring charge in the amount of $472,069 in the quarter
ended September 30, 2008. The components of the restructuring charge are
as follows:
|
Accelerated
vesting of stock options previously issued to the former
CEO
|
$
|
138,434
|
|||
Accrued
severance and benefits to former employees whose positions were
eliminated
|
149,262
|
||||
Write-off
of raw materials and packaging inventory primarily related to
SATIATRIM®
|
184,373
|
||||
$
|
472,069
|
During
the fourth quarter of 2008, the Company paid $127,926 towards the $149,262
obligation due to former employees.
|
|
[2]
|
Cash
and cash equivalents:
|
The
Company considers all highly liquid investments with original maturities
of three months or less at the date of purchase to be cash
equivalents.
|
|
[3]
|
Accounts
receivable:
|
Accounts
receivable consist of trade receivables recorded at original invoice
amount, less an estimated allowance for uncollectible accounts. Trade
credit is generally extended on a short-term basis; thus trade receivables
do not bear interest. Trade receivables are periodically evaluated for
collectibility by considering a number of factors including the length of
time an invoice is past due, the customers’ credit worthiness and
historical bad debt experience. Changes in the estimated collectibility of
trade receivables are recorded in the results of operations for the period
in which the estimate is revised. Trade receivables that are deemed
uncollectible are offset against the allowance for uncollectible accounts.
The Company generally does not require collateral for trade
receivables.
|
|
[4]
|
Inventories:
|
Inventories
are recorded at the lower of cost or market using the first-in, first-out
(“FIFO”) method. The Company determines its reserve for obsolete inventory
by considering a number of factors, including product shelf life,
marketability, and obsolescence. The Company determines the need to write
down inventories by analyzing product expiration, market conditions, and
salability of its products.
|
[5]
|
Property
and equipment:
|
Property
and equipment are stated at cost and are depreciated using the
straight-line method over their estimated useful lives ranging from 2 to 5
years.
|
|
[6]
|
Loss
per share:
|
Basic
loss per common share is computed by dividing net loss applicable to
common shareholders by the weighted average number of common shares
outstanding during the year. The dilutive effect of the outstanding stock
warrants and options is computed using the treasury stock method. For the
year ended December 31, 2008, diluted loss per share did not include
the effect of 2,942,250 options outstanding and 27,500 warrants
outstanding, respectively, as their effect would be anti-dilutive. For the
year ended December 31, 2007, diluted loss per share did not include
the effect of 2,408,750 options outstanding and 938,930 warrants
outstanding, respectively, as their effect would be
anti-dilutive.
|
|
[7]
|
Revenue
recognition:
|
Sales
are recognized when all of the following criteria are met:
(1) persuasive evidence that an arrangement exists; (2) delivery
has occurred or services have been rendered; (3) the seller’s price
to the buyer is fixed and determinable; and, (4) collectibility is
reasonably assured. Sales are recorded net of incentives paid and
discounts offered to customers.
|
|
The
Company has a purchasing agreement with a significant customer for all
products sold to this customer whereby all unsold product is subject to a
right of return provision if certain minimum levels of retail sales in a
12-month period of time from the date of initial sale are not achieved.
The Company recognizes revenue when its major customer sells through its
products to the consumer. The Company uses this criteria due to the
inability to accurately estimate future returns from this customer as the
Company has previously agreed to accept returns/discounts of product from
this customer that it was not contractually obligated to do so as well as
because the Company entered into a new purchasing agreement with this
customer that increased certain sell-through minimums. The Company is
currently evaluating its procedures to estimate future returns from this
customer. As of December 31, 2008 and 2007, shipments to this customer
amounting to $347,945 and $559,876, respectively, have been reflected as
deferred revenue in the Company’s balance sheet.
|
|
[8]
|
Research
and development:
|
Costs
of research and development activities are expensed as
incurred.
|
|
[9]
|
Advertising
costs:
|
Advertising
costs are expensed as incurred. During 2008 and 2007, the Company recorded
advertising expense of $326,286 and $158,716,
respectively.
|
|
[10]
|
Stock-based
compensation:
|
The
Company accounts for equity instrument issuances in accordance with
Statement of Financial Accounting Standards (“SFAS”) 123R, “Share-Based
Payment”. Such equity issuances encompass transactions in which an entity
exchanges its equity instruments for goods or services including such
transactions in which an entity obtains employee and/or director services
in share-based payment transactions and issuances of stock options to
employees. The Company recorded a charge of $473,520 in the year ended
December 31, 2008, representing the effect on loss from operations, loss
before income taxes, and net loss. Of this amount, $138,434 related to the
acceleration of stock options vesting to the former CEO as is included in
restructuring expense. The Company recorded a charge of $272,334 in the
year ended December 31, 2007, representing the effect on loss from
operations, loss before income taxes, and net
loss.
|
The
fair value of each option grant on the date of grant is estimated using
the Black-Scholes option-pricing model with a volatility ranging from 99%
to 104% for 2008 and from 110% to 119% for 2007, expected life of the
options of 5 years, risk-free interest rate of approximately 3% in 2008
and 4% in 2007 and a dividend yield of 0%. The weighted average fair
values of options granted during the years ended December 31, 2008
and 2007 were $0.35 and $0.76, respectively. Also see Note
N.
|
|
[11]
|
Segment
information:
|
The
Company operates in one business segment: the design, development and
marketing of dietary and nutritional supplements that enhance health and
well-being. Segment disclosures relate to sales data for geographic
reasons only.
|
|
[12]
|
Income
taxes:
|
The
Company recognizes deferred tax liabilities and assets for the expected
future tax consequences of events that have been included in the financial
statements or tax returns. Under this method, deferred tax liabilities and
assets are determined on the basis of the differences between the tax
basis of assets and liabilities and their respective financial reporting
amounts (“temporary differences”) at enacted tax rates in effect for the
years in which the differences are expected to reverse. Any resulting
deferred tax asset is reduced, if necessary, by a valuation allowance for
any tax benefits that are not expected to be realized. Effective January
1, 2007, the Company adopted Financial Interpretation No. 48, “Accounting
for Uncertainty in Income Taxes”, (“FIN 48”). The impact of the adoption
of FIN 48 had no material effect on the Company’s results of operations or
financial position.
|
|
[13]
|
Impairment
of long-lived assets:
|
Long-lived
assets, to be held and used, are reviewed for impairment whenever events
or changes in circumstances indicate that the related carrying amounts may
not be recoverable using expected future undiscounted cash flows. When
required, impairment losses on assets to be held and used are recognized
based on the excess of the assets’ carrying amount over their fair values
as determined by selling prices for similar assets or application of other
appropriate valuation techniques. Long-lived assets to be disposed of are
reported at the lower of their carrying amounts or fair values less
disposal costs.
|
|
[14]
|
Comprehensive
income (loss):
|
The
Company does not have any comprehensive income (loss) items at
December 31, 2008 and 2007.
|
|
[15]
|
Recent
accounting pronouncements:
|
In
September 2006, the FASB issued Statement of Financial Accounting
Standards No. 157, “Fair Value Measurements” (“SFAS 157”). SFAS 157
defines fair value, establishes a framework for measuring fair value, and
expands disclosure requirements regarding fair value measurement. Where
applicable, this statement simplifies and codifies fair value related
guidance previously issued within U.S. generally accepted accounting
principles. SFAS 157 is effective for financial statements issued for
fiscal years beginning after November 15, 2007, and interim periods within
those fiscal years. SFAS 157 did not have a material impact on its results
of operations or financial condition upon adoption.
|
|
In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for
Financial Assets and Financial Liabilities - Including an Amendment of
FASB Statement No.115 (“SFAS 159”). SFAS 159 provides companies with an
option to measure, at specified election dates, certain financial
instruments and other items at fair value that are not currently measured
at fair value. A company that adopts SFAS 159 will report unrealized gains
and losses on items for which the fair value option has been elected in
its financial results during each subsequent reporting date. SFAS 159 also
establishes presentation and disclosure requirements designed to
facilitate comparisons between entities that choose different measurement
attributes for similar types of assets and liabilities. SFAS 159 is
effective for fiscal years beginning after November 15, 2007. SFAS 159 did
not have a material impact on its results of operations or financial
condition upon adoption.
|
In
December 2007, the SEC issued Staff Accounting Bulletin No. 110 “Amendment
of Topic 14, Share-Based Payment”, (“SAB 110”). SAB 110 expresses the
views of the staff regarding the use of a “simplified” method, as
discussed in SAB No. 107, in developing an estimate of the expected term
of “plain vanilla” share options in accordance with SFAS 123R. SAB 110 did
not have a material impact on its results of operations or financial
condition upon adoption.
|
|
In
May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally
Accepted Accounting Principles” (“SFAS 162”). SFAS 162 sets forth the
level of authority to a given accounting pronouncement or document by
category. Where there may be conflicting guidance between two categories,
the more authoritative category will prevail. SFAS 162 became effective
November 14, 2008 and the Company does not expect SFAS 162 to have a
material impact on its results of operations, financial condition, or
current practices.
|
|
[16]
|
Use
of estimates:
|
The
preparation of financial statements in conformity with accounting
principles generally accepted in the United States of America requires
management to make certain estimates and assumptions that affect the
reported amounts of assets, liabilities and disclosure of contingent
assets and liabilities at the date of the financial statements and the
reported amount of revenue and expenses during the reporting period.
Actual results may differ from these estimates.
|
|
[17]
|
Shipping
and handling fees and costs:
|
Shipping
and handling costs are included in cost of sales.
|
|
[18]
|
Reclassification
|
The
Company reclassified $917,510 of sales and marketing expenses from general
and administrative expenses as well as reclassified $96,374 of
depreciation expense to general and administrative expense in 2007 to
conform to current year
presentation.
|
2008
|
2007
|
|||||||
Raw
materials (at contract manufacturer)
|
$ | 207,286 | $ | 266,624 | ||||
Work
in process (at contract manufacturer)
|
— | 67,920 | ||||||
Packaging
supplies (at third party warehouse)
|
42,861 | 56,480 | ||||||
Finished
goods (at third party warehouse)
|
902,132 | 1,358,378 | ||||||
Finished
goods (on consignment)
|
156,037 | 261,044 | ||||||
$ | 1,308,316 | $ | 2,010,446 |
2008
|
2007
|
|||||||
Furniture
and equipment
|
$ | 783,098 | $ | 616,675 | ||||
Molds
and dies
|
204,782 | 159,494 | ||||||
987,880 | 776,169 | |||||||
Less
accumulated depreciation
|
751,159 | 591,162 | ||||||
$ | 236,721 | $ | 185,007 |
2008
|
2007
|
|||||||
Installment
note payable to insurance finance company due in monthly installments of
$8,168, including interest at 6.48% through February 2008
|
$ | — | $ | 16,205 | ||||
Installment
note payable to insurance finance company due in monthly installments of
$5,456, including interest at 5.00% through March 2009
|
16,231 | |||||||
Installment
note payable to insurance finance company due in monthly installments of
$4,378, including interest at 6.10% through October 2009
|
42,579 | — | ||||||
$ | 58,810 | $ | 16,205 |
[1]
|
Employment
agreements:
|
The
Company entered into a new employment agreement on January 1, 2007, with
the CEO of the Company that provided for minimum annual compensation of
$295,000. On August 5, 2008, the Company entered into a Separation
Agreement with the CEO whereby the Company would continue to pay the
$295,000 salary for twelve months in exchange for a twelve-month
non-compete provision. Also, all previously unvested options vested on
this date. See Note 1.
|
|
The
Company entered into an employment agreement on January 3, 2008, with the
new President and Chief Operating Officer of the Company that provides for
minimum annual compensation of $295,000. In the event of a change in
control, as defined in the employment agreement, and a contemporaneous or
subsequent termination of Employee for Good Reason, the President shall be
paid, as additional compensation, a lump sum equal to half his annual base
salary in effect immediately prior to the change in control. If the
President is terminated without cause, as defined in the employment
agreement, the Company shall pay the President, at the time of
termination, an amount equal to his annual base salary which would have
been paid during a period beginning on the date of termination of
employment and ending on the later of the scheduled termination date, as
defined in the employment agreement, or the first anniversary of the
termination date, to be offset by any compensation earned in other
full-time employment. This employment agreement was amended on August 5,
2008 removing the title of Chief Operating Officer and adding the title of
Chief Executive Officer.
|
|
The
Company entered into an employment agreement on January 3, 2008, with the
new Vice President, Product Development and Supply Chain of the Company
that provides for minimum annual compensation of $190,000. If this Vice
President is terminated without cause, as defined in the employment
agreement, the Company shall pay him, at the time of termination, an
amount equal to four months of his base salary which would have been paid
during a period beginning on the date of termination of employment and
ending on the later of the scheduled termination date, as defined in the
employment agreement, or four months from the termination date, to be
offset by any compensation earned in other full-time
employment.
|
|
[2]
|
Lease:
|
The
Company has a lease agreement for office space for the rental of 5,500
square feet expiring June 2012.
|
|
The
future minimum lease payments due under the lease is as
follows:
|
Years
Ending
December
31,
|
|||||||
2009
|
$
|
140,250
|
|||||
2010
|
143,000
|
||||||
2011
|
148,500
|
||||||
2012
|
75,625
|
||||||
$
|
507,375
|
Rent expense amounted to $140,608 and $118,145 in 2008 and 2007, respectively. |
Option
Shares
|
Vested
Shares
|
Exercise
Price
Per
Common
Share
|
Weighted
Average
Exercise
Price
Per
Share
Outstanding
|
|||||||||||
Balance,
January 1, 2007
|
2,011,500
|
1,069,500
|
$0.20
- $3.80
|
$
|
1.12
|
|||||||||
Granted/vested
during the year
|
741,000
|
418,668
|
$0.65
- $2.14
|
$
|
0.76
|
|||||||||
Exercised
during the year
|
(81,000
|
)
|
(81,000
|
)
|
$0.20
- $1.00
|
$
|
0.65
|
|||||||
Expired
during the year
|
(333,000
|
)
|
(333,000
|
)
|
$2.79
- $3.80
|
$
|
2.89
|
|||||||
Balance,
December 31, 2007
|
2,338,500
|
1,074,168
|
$0.20
- $2.14
|
$
|
0.77
|
|||||||||
Granted/vested
during the year
|
657,500
|
601,333
|
$0.23
- $0.55
|
$
|
0.35
|
|||||||||
Exercised
during the year
|
—
|
—
|
—
|
—
|
||||||||||
Expired
during the year
|
(119,000
|
)
|
(119,000
|
)
|
$0.20
- $1.92
|
$
|
0.97
|
|||||||
Balance,
December 31, 2008
|
2,877,000
|
|
1,556,501
|
|
$0.20
- $2.14
|
$
|
0.67
|
|||||||
|
||||||||||||||
Aggregate
Intrinsic Value, December
31, 2008
|
$
|
—
|
$
|
—
|
Range
of
Exercise
Prices
|
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life
(in Years)
|
Weighted
Average
Exercise
Price
|
Number
Exercisable
|
Weighted
Average
Exercise
Price
|
|||||||||||||
$0.31
- $2.00
|
2,851,000
|
2.92
|
$
|
0.66
|
1,533,501
|
$
|
0.78
|
|||||||||||
$2.01
- $4.00
|
26,000
|
3.19
|
$
|
2.12
|
23,000
|
$
|
2.13
|
|||||||||||
2,877,000
|
2.92
|
$
|
0.67
|
1,556,501
|
$
|
0.80
|
Option
Shares
|
Vested
Shares
|
Exercise
Price
Per
Common
Share
|
Weighted
Average
Exercise
Price
Per
Share
Outstanding
|
|||||||||||
Balance,
January 1, 2007
|
90,500
|
90,500
|
$0.20
- $4.88
|
$
|
1.35
|
|||||||||
Granted/vested
during the year
|
2,250
|
2,250
|
$1.21
- $2.10
|
$
|
1.61
|
|||||||||
Expired
during the year
|
(22,500
|
)
|
(22,500
|
)
|
$0.90
- $4.88
|
$
|
4.36
|
|||||||
Balance,
December 31, 2007
|
70,250
|
70,250
|
$0.20
- $2.10
|
$
|
0.39
|
|||||||||
Granted/vested
during the year
|
—
|
—
|
—
|
—
|
||||||||||
Expired
during the year
|
(5,000
|
)
|
(5,000
|
)
|
$0.26
- $1.23
|
$
|
0.75
|
|||||||
Balance,
December 31, 2008
|
65,250
|
65,250
|
$0.20
- $2.10
|
$
|
0.37
|
Range
of
Exercise
Prices
|
Number
Outstanding
and
Exercisable
|
Weighted
Average
Remaining
Contractual
Life
(in Years)
|
Weighted
Average
Exercise
Price
|
||||||||
$0.20
- $2.00
|
64,250
|
0.61
|
$
|
0.34
|
|||||||
$2.10
|
1,000
|
1.16
|
$
|
2.10
|
|||||||
65,250
|
0.62
|
$
|
0.37
|
Warrants
|
Exercise
Price
Per
Common
Share
|
Weighted
Average
Exercise
Price
Per
Common
Share
|
|||||||||
Balance,
January 1, 2007
|
1,351,710
|
$0.63
- $0.88
|
$
|
0.64
|
|||||||
Exercised
during the year
|
(412,780
|
)
|
$0.63
|
$
|
0.63
|
||||||
Balance,
December 31, 2007
|
938,930
|
$0.63
- $0.88
|
$
|
0.64
|
|||||||
Expired
during the year
|
(911,430
|
)
|
$0.63
|
$
|
0.63
|
||||||
Balance,
December 31, 2008
|
27,500
|
$0.88
|
$
|
0.88
|
2008
|
2007
|
|||||||||||||||
Amount
|
Percent
|
Amount
|
Percent
|
|||||||||||||
U.S.
federal income tax provision (benefit) at federal statutory
rate
|
$ | (698,020 | ) | 35 | % | $ | (446,620 | ) | 35 | % | ||||||
Effect
of state taxes, net of federal benefit
|
(119,670 | ) | 6 | % | (76,560 | ) | 6 | % | ||||||||
Change
in valuation allowance
|
642,300 | (32 | %) | 411,600 | (32 | %) | ||||||||||
Stock
compensation expense, (SFAS123R)
|
173,830 | (9 | %) | 112,700 | (9 | %) | ||||||||||
Other
|
1,560 | 0 | % | (1,120 | ) | (0 | %) | |||||||||
$ | 0 | 0 | % | $ | 0 | 0 | % |
2008
|
2007
|
|||||||
Net
operating loss carryforwards
|
$ | 5,657,000 | $ | 4,931,000 | ||||
Inventory
reserve
|
17,000 | 72,000 | ||||||
Other
|
33,000 | 62,000 | ||||||
Valuation
allowance
|
(5,707,000 | ) | (5,065,000 | ) | ||||
Deferred
tax asset
|
$ | - 0 - | $ | - 0 - |
[1]
|
Concentrations
of credit risk:
|
Financial
instruments, which potentially subject the Company to concentrations of
credit risk, consist primarily of cash, cash equivalents and trade
accounts receivable.
|
|
The
Company has concentrated its credit risk for cash by maintaining
substantially all of its depository accounts in two financial
institutions. Amounts at one of the institutions are insured by the
Federal Deposit Insurance Corporation up to $250,000 and amounts at the
other institution are insured by the Securities Investor Protection
Corporation up to $500,000. Uninsured balances aggregated approximately
$581,000 at December 31, 2008 that exceeded these insured amounts. These
financial institutions have a strong credit rating, and management
believes that credit risk relating to these deposits is
minimal.
|
|
The
Company does not require collateral on its trade accounts receivable.
Historically, the Company has not suffered significant losses with respect
to trade accounts receivable.
|
|
[2]
|
Fair
value of financial instruments:
|
Cash,
cash equivalents, accounts receivable, accounts payable and notes payable
approximate their fair values due to the short-term maturity of these
instruments.
|
|
[3]
|
Major
customers:
|
For
the years ended December 31, the Company had product sales from two
customers that accounted for approximately 18% and 15% in 2008 and 21% and
15% in 2007, of net product sales. Accounts receivable outstanding related
to these customers at December 31, 2008 and 2007 were $200,590 and
$435,845, respectively. Deferred revenue from one of these customers was
$347,945 as of December 31, 2008 and $559,876 as of December 31,
2007. Such amounts are included in the accompanying balance sheet. The
loss of these customers, a significant reduction in purchase volume by
these customers, or the financial difficulty of such customers, for any
reason, could significantly reduce our revenues. We have no agreement with
or commitment from either of these customers with respect to future
purchases.
|
|
[4]
|
Major
vendors:
|
Two
suppliers accounted for approximately 62% and 16%, respectively, of total
inventory purchases for the year ended December 31, 2008 and two suppliers
accounted for 69% and 22%, respectively, of total inventory purchases for
the year ended December 31, 2007. At December 31, 2008, amounts due to
these two vendors represented approximately 23% and 0%, respectively, of
accounts payable and accrued expenses. At December 31, 2007, amounts due
to two vendors represented approximately 45% and 1%, respectively, of
accounts payable and accrued
expenses.
|
2008
|
2007
|
||||||||
United
States
|
$ | 6,509,508 | $ | 6,778,183 | |||||
Canada
|
258,973 | 208,649 | |||||||
Other
|
467,510 | 441,025 | |||||||
Total
|
$ | 7,235,991 | $ | 7,427,857 |